Princeton Global Asset Management LLC Sells 376 Shares of Zoetis Inc. (NYSE:ZTS)

Princeton Global Asset Management LLC decreased its position in shares of Zoetis Inc. (NYSE:ZTS) by 12.8% in the 1st quarter, HoldingsChannel.com reports. The institutional investor owned 2,551 shares of the company’s stock after selling 376 shares during the period. Princeton Global Asset Management LLC’s holdings in Zoetis were worth $420,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of ZTS. Mission Wealth Management LP grew its position in Zoetis by 2.0% during the 4th quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock worth $479,000 after acquiring an additional 59 shares during the last quarter. VeraBank N.A. grew its holdings in shares of Zoetis by 4.1% during the fourth quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after purchasing an additional 62 shares during the last quarter. HUB Investment Partners LLC increased its stake in shares of Zoetis by 4.7% in the fourth quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after buying an additional 62 shares in the last quarter. Coppell Advisory Solutions LLC raised its holdings in shares of Zoetis by 18.0% in the fourth quarter. Coppell Advisory Solutions LLC now owns 420 shares of the company’s stock valued at $68,000 after buying an additional 64 shares during the last quarter. Finally, Deseret Mutual Benefit Administrators lifted its position in Zoetis by 6.6% during the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock worth $170,000 after buying an additional 65 shares in the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Price Performance

Shares of ZTS stock opened at $170.15 on Friday. The firm’s 50 day moving average price is $157.41 and its two-hundred day moving average price is $164.37. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. Zoetis Inc. has a 52-week low of $139.70 and a 52-week high of $200.33. The stock has a market cap of $75.75 billion, a PE ratio of 31.11, a PEG ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The company had revenue of $2.22 billion for the quarter, compared to the consensus estimate of $2.20 billion. During the same quarter in the prior year, the business posted $1.38 EPS. The firm’s quarterly revenue was up 1.4% on a year-over-year basis. As a group, analysts forecast that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Friday, July 18th will be issued a dividend of $0.50 per share. This represents a $2.00 dividend on an annualized basis and a yield of 1.18%. The ex-dividend date is Friday, July 18th. Zoetis’s dividend payout ratio (DPR) is currently 35.91%.

Insider Transactions at Zoetis

In related news, EVP Roxanne Lagano sold 326 shares of Zoetis stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now owns 15,781 shares of the company’s stock, valued at $2,682,770. This trade represents a 2.02% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total transaction of $201,029.40. Following the transaction, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This represents a 9.71% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 2,188 shares of company stock worth $367,289. 0.18% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

ZTS has been the subject of several research reports. UBS Group lowered their price objective on shares of Zoetis from $189.00 to $170.00 and set a “neutral” rating for the company in a research report on Wednesday, May 7th. Morgan Stanley lowered their price target on shares of Zoetis from $243.00 to $238.00 and set an “overweight” rating for the company in a report on Friday, February 14th. Piper Sandler boosted their price objective on shares of Zoetis from $205.00 to $210.00 and gave the stock an “overweight” rating in a research report on Monday, May 12th. Stifel Nicolaus decreased their price objective on Zoetis from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Monday, April 14th. Finally, Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. One investment analyst has rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $212.75.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.